Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Wednesday, June 11, 2025 1 min read
Key Takeaway: RAD has been granted Fast Track designation by the US FDA for its product RAD101, which is aimed at imaging metastases. This designation is intended to facilitate the development and review process, potentially accelerating the availability of RAD101 to patients. The designation highlights the product's promise in addressing unmet medical needs in cancer imaging.
Price reaction · baseline $4.8 (2025-06-11T19:00:00.000Z) · hit during market hours · 2 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD101 has received Fast Track designation from the FDA.
  • This designation may expedite the development and review process.
  • The focus on metastases imaging indicates potential for significant clinical impact.

Full Press Release Details

• Announcements
• Price Sensitive , Progress Report
• June 11, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• October 31, 2023
• Announcements
• December 19, 2024
• Announcements
• November 29, 2022
• Investor Presentations
• March 10, 2026

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is RAD101?

RAD101 is a product developed by RADX aimed at imaging metastases.

What does Fast Track designation mean?

Fast Track designation is an FDA program to expedite the development and review of drugs.

Why is RAD101 important?

RAD101 addresses unmet medical needs in cancer imaging, potentially improving patient outcomes.

Who granted the Fast Track designation?

The Fast Track designation was granted by the US FDA.

Tags: RADX Viatris Investor Conferences Healthcare FDA Fast Track RAD101 metastases imaging
Last updated: Jun 11, 2025